Chronic treatment of astrocytes with therapeutically relevant fluoxetine concentrations enhances cPLA2 expression secondary to 5-HT2B-induced, transactivation-mediated ERK1/2 phosphorylation.
about
Molecular and Functional Characterization of Bacopa monniera: A Retrospective ReviewSignal Transduction in Astrocytes during Chronic or Acute Treatment with Drugs (SSRIs, Antibipolar Drugs, GABA-ergic Drugs, and Benzodiazepines) Ameliorating Mood DisordersFluoxetine affects GluK2 editing, glutamate-evoked Ca(2+) influx and extracellular signal-regulated kinase phosphorylation in mouse astrocytes.Chronic SSRI stimulation of astrocytic 5-HT2B receptors change multiple gene expressions/editings and metabolism of glutamate, glucose and glycogen: a potential paradigm shift.Fluoxetine and all other SSRIs are 5-HT2B Agonists - Importance for their Therapeutic Effects.Decrease of gene expression of astrocytic 5-HT2B receptors parallels development of depressive phenotype in a mouse model of Parkinson's disease.Pharmacometabolomic mapping of early biochemical changes induced by sertraline and placebo.Density of GFAP-immunoreactive astrocytes is decreased in left hippocampi in major depressive disorder.Cell type-specific gene expression and editing responses to chronic fluoxetine treatment in the in vivo mouse brain and their relevance for stress-induced anhedonia.5-HT2 ligands in the treatment of anxiety and depression.Participation of microRNA 124-CREB pathway: a parallel memory enhancing mechanism of standardised extract of Bacopa monniera (BESEB CDRI-08).Fluoxetine ameliorates behavioral and neuropathological deficits in a transgenic model mouse of α-synucleinopathy.Four mood stabilizers commonly induce FEZ1 expression in human astrocytes.Trazodone regulates neurotrophic/growth factors, mitogen-activated protein kinases and lactate release in human primary astrocytes.5-HT2B receptors are expressed on astrocytes from brain and in culture and are a chronic target for all five conventional 'serotonin-specific reuptake inhibitors'.Gastrodin ameliorates depressive-like behaviors and up-regulates the expression of BDNF in the hippocampus and hippocampal-derived astrocyte of rats.Rosmarinic acid ameliorates depressive-like behaviors in a rat model of CUS and Up-regulates BDNF levels in the hippocampus and hippocampal-derived astrocytes.Biphasic Regulation of Caveolin-1 Gene Expression by Fluoxetine in Astrocytes: Opposite Effects of PI3K/AKT and MAPK/ERK Signaling Pathways on c-fos.Biochemical effects of venlafaxine on astrocytes as revealed by 1H NMR-based metabolic profiling.Cell type-specific in vivo expression of genes encoding signalling molecules in the brain in response to chronic mild stress and chronic treatment with fluoxetine.Expression of nucleoside transporter in freshly isolated neurons and astrocytes from mouse brain.The Effect of Antidepressants on Mesenchymal Stem Cell Differentiation.
P2860
Q26786001-8AD80C2F-029A-445A-B133-DF525461632AQ27006485-94670C7D-2A99-48BB-A372-9F617B661E1FQ30474244-E297CF33-07BD-4481-9B47-AF50C8D224C0Q30906677-AF96A1A5-1EB8-4343-8687-FB06CC565191Q34391633-DBBE2B23-58AD-4E62-B9EC-DA857664F03BQ36124822-72ABD34D-F3F4-4E85-BCEC-C7A94204A04EQ36593835-76D9ABB9-2CBB-4853-AC5B-41FF65D3EAD2Q36812629-2F2A3568-0F11-4FED-A7A0-1F2FFA29D325Q38019843-96509C2C-3EC6-474F-94FD-A4BB0DB54A75Q38037141-C32A7178-CE79-498C-8D5A-9A68645880A6Q38323159-C8F2A194-AE94-4EB5-8C52-BB46E8164F18Q39405702-7249A8A1-3447-4936-B570-511D309DDAB6Q39454883-9D9B460A-F714-4161-97B9-27185B638774Q41850897-EDBAEC91-3AEF-4FEB-AB01-6D4A2552C668Q42905649-4689A46C-719A-48A2-BC3F-F6FEA01E1802Q44285325-934E5CBF-66F9-4D62-B643-EF55B9C34CEAQ45790785-4D0D3F8E-C948-4ADC-9EBB-C53805126BACQ47152588-26806795-65B5-4207-820D-0B726C3AA300Q48001597-DBA394B4-E712-4093-ADAE-7A5F694EBF4BQ48086194-29442BAF-D681-4153-8CBF-9D24DDC1550FQ49045397-734A7506-0309-4BEE-90DE-65B418E11A21Q55313740-A934AECE-1374-45F4-A817-C717A0E07E82
P2860
Chronic treatment of astrocytes with therapeutically relevant fluoxetine concentrations enhances cPLA2 expression secondary to 5-HT2B-induced, transactivation-mediated ERK1/2 phosphorylation.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
Chronic treatment of astrocyte ...... diated ERK1/2 phosphorylation.
@en
Chronic treatment of astrocyte ...... diated ERK1/2 phosphorylation.
@nl
type
label
Chronic treatment of astrocyte ...... diated ERK1/2 phosphorylation.
@en
Chronic treatment of astrocyte ...... diated ERK1/2 phosphorylation.
@nl
prefLabel
Chronic treatment of astrocyte ...... diated ERK1/2 phosphorylation.
@en
Chronic treatment of astrocyte ...... diated ERK1/2 phosphorylation.
@nl
P2093
P2860
P1433
P1476
Chronic treatment of astrocyte ...... diated ERK1/2 phosphorylation.
@en
P2093
P2860
P2888
P356
10.1007/S00213-009-1631-3
P50
P577
2009-08-07T00:00:00Z
P6179
1000911114